Differences in sleep and awakening quality between 51 @entity170 @entity1 and normal controls were evaluated. In a subsequent double-blind, placebo-controlled, comparative, randomized, three-arm trial (Climodien 2/3 = @entity2691 2 mg + the progestogen dienogest 3 mg = regimen A, @entity2691 2 mg = regimen @entity8323 , and placebo = regimen P), the effects of 2 months of hormone replacement therapy were investigated, followed by a 2-month open-label phase in which all @entity1 received Climodien 2/2 ( @entity8323 2 mg + @entity18725 2 mg = regimen A*). Polysomnography at baseline demonstrated significantly deteriorated sleep initiation and maintenance, increased S1 and decreased S2 in @entity1 . Subjective sleep and awakening quality, well-being, morning drive, wakefulness, memory and reaction time performance were deteriorated too. Treatment with both regimen A and regimen @entity8323 induced a moderate, although nonsignificant, improvement in the primary efficacy variable wakefulness during the total sleep period compared with baseline, while under placebo no changes occurred. Secondary efficacy variables concerning sleep initiation and maintenance, and sleep architecture showed similar findings. The @entity386 and @entity27 indices improved significantly under regimen A, compared with both baseline and placebo. Subjective sleep and awakening quality improved significantly after regimen A and @entity8323 compared with baseline, with the drug-induced changes being superior to those induced by placebo. In the open-label phase, subjective @entity25 improved further, significantly in the former regimen A group. Awakening quality, somatic complaints and morning thymopsyche did not yield any significant findings. Concerning morning noopsychic performance, memory improved significantly after regimen A compared with baseline, fine motor activity after regimen @entity8323 . Reaction time performance increased with all three compounds. In conclusion, Climodien significantly improved subjective @entity25 , the @entity386 and @entity27 indices of @entity170 @entity1 , while it only marginally improved variables concerning objective sleep and awakening quality.

Insomnia related to @entity170 and hormone replacement therapy: sleep laboratory studies on baseline differences between XXXX and controls and double-blind, placebo-controlled investigations on the effects of a novel estrogen-progestogen combination (Climodien, Lafamme) versus estrogen alone.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity2691 :: ('MESH:C015854', 'Chemical') :: ['estradiol valerate'] @entity18725 :: ('MESH:C023635', 'Chemical') :: ['dienogest'] @entity170 :: ('MESH:D010024', 'Disease') :: ['insomniac postmenopausal syndrome'] @entity27 :: ('MESH:D020181', 'Disease') :: ['apnea-hypopnea'] @entity25 :: ('MESH:D012893', 'Disease') :: ['sleep quality'] @entity8323 :: ('MESH:D004819', 'Disease') :: ['EV'] @entity386 :: ('MESH:D001049', 'Disease') :: ['apnea']
@entity1 :: (9606,Species) :: ['patients']
